Development and application of a novel aldehyde nanoparticle-based amplified luminescent proximity homogeneous assay for rapid quantitation of pancreatic stone protein

Xiang, Zhongyi; Chen, Xindong; Zhou, Xiumei; Qin, Yuan; Zhao, Xueqin; Wang, Yigang; Li, Qian; Huang, Biao

doi:10.1016/j.cca.2022.08.020

Cited by 9 publications

(9 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, the fluorescence signal depends on the antibody–antigen reaction, which binds the donor and acceptor beads to form detectable immune complexes (donor beads and acceptor beads in close proximity <200 nm) ( Armstrong et al, 2018 ). With this microsphere-based approach, the relatively large surface area provided by the nanospheres suspended in the assay solution facilitates the rapid onset of the immune response; coupled with the fact that each donor beads can generate 60,000 single-linear oxygen molecules, such a large surface area can greatly amplify the signal ( Li et al, 2018 ; Xiang et al, 2022 ), greatly enhanced response sensitivity.…”

Section: Discussionmentioning

confidence: 99%

“…The donor beads are coated with a photosensitizer (i.e., benzene dimethyl blue); under light excitation at 680 nm, oxygen in the environment near the surface of the donor beads is decomposed and converted into singlet oxygen, which migrates to the acceptor beads. The surface of the acceptor beads is coated with a luminescent agent, dimethylthiophene derivative, chelated with the rare earth atom europium; when the energy is finally transferred to the rare earth atom europium, the excitation light at 615 nm is excited ( Xiang et al, 2022 ). The emission has high intensity, long life, and sharp peaks ( Liu et al, 2013 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Development and application of an amplified luminescent proximity homogeneous assay-linked immunosorbent assay for the accurate quantification of kidney injury molecule-1

Fu,

Sun,

Qin

et al. 2024

Front. Mol. Biosci.

Self Cite

View full text Add to dashboard Cite

Background: Kidney injury molecule-1 (Kim-1), a specific marker of kidney injury, is usually not expressed in normal kidneys or at very low levels but is highly expressed in injured renal tubular epithelial cells until the damaged cells recover completely. Therefore, we aimed to develop an efficient and highly sensitive assay to accurately quantify Kim-1 levels in human serum and urine.Methods: In this study, a novel immunoassay was developed and named amplified luminescent proximity homogeneous assay-linked immunosorbent assay (AlphaLISA). Anti-Kim-1 antibodies can be directly coupled to carboxyl-modified donor and acceptor beads for the rapid detection of Kim-1 by double-antibody sandwich method. Serum and urine samples for Kim-1 measurements were obtained from 129 patients with nephropathy and 17 healthy individuals.Results: The linear range of Kim-1 detected by AlphaLISA was 3.83–5000 pg/mL, the coefficients of variation of intra-assay and inter-assay batches were 3.36%–4.71% and 5.61%–11.84%, respectively, and the recovery rate was 92.31%–99.58%. No cross reactions with neutrophil gelatinase-associated lipocalin, liver-type fatty acid binding protein, and matrix metalloproteinase-3 were observed. A good correlation (R2 = 0.9086) was found between the findings of Kim-1-TRFIA and Kim-AlphaLISA for the same set of samples. In clinical trials, both serum and urine Kim-1 levels were significantly higher in patients with nephropathy than in healthy individuals, especially in patients with acute kidney injury. Furthermore, serum Kim-1 was superior to urinary Kim-1 in distinguishing between patients with nephropathy and healthy individuals.Conclusion: The developed Kim-1-AlphaLISA is highly efficient, precise, and sensitive, and it is suitable for the rapid detection of patients with acute kidney injury.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Development and application of an amplified luminescent proximity homogeneous assay-linked immunosorbent assay for the accurate quantification of kidney injury molecule-1

Fu,

Sun,

Qin

et al. 2024

Front. Mol. Biosci.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Searching for clinical studies of PSP and infection or sepsis in PubMed, we identified 1 prospective multicenter study, 29 20 prospective observational studies (Table 3 and 4), 2 meta-analyses, 30,31 2 literature reviews, 32,33 1 economic study, 34 2 technology study, 35,36 1 case report, 37 3 Covid-19 studies, [38][39][40] 1 book chapter, 41 2 point-of-view articles. 42,43 From the PubMed citations, we excluded 8 children studies, [44][45][46][47][48][49][50][51] 3 neonate studies, [52][53][54] 1 post-mortem study, 55 1 study in women for pregnancy-related disease, 56 1 PSP and diabetes study, 57 2 study protocols, 58,59 1 letter, 60 1 editorial, 61 4 comments, [62][63][64][65] and 1 published erratum.…”

Section: Pancreatic Stone Protein Clinical Studies For Infection and ...mentioning

confidence: 99%

Usefulness of pancreatic stone protein measurement to screen and diagnose sepsis in the context of the Surviving Sepsis Campaign recommendations.

Ventura,

Eggimann,

Daix

et al. 2023

MRAJ

View full text Add to dashboard Cite

Sepsis occurs yearly in 48.9 million people worldwide of whom 11 million will die. Sepsis is defined as a life-threatening dysregulated reaction of the body in response to a bacterial infection, leading to organ dysfunction. The Surviving Sepsis Campaign (SSC) made numerous recommendations for sepsis diagnosis and treatment using an evidence-based medicine approach. Frequently, levels of evidence of these recommendations are poor and lack clear clinical guidance. Interestingly, the SSC guidelines strongly recommend, with a moderate quality of evidence, screening of nosocomial sepsis in acutely ill hospitalized “high-risk patients”. The definition of acutely ill and high-risk patients is not specified, nor it is indicated which tools should be used. The diagnosis of infection and the subsequent administration of antibiotics relies solely on rapid clinical assessment, as recommended by the Best Practice Statement. Again, the elements used for clinical assessment are poorly defined, encompassing patient history, clinical examination, and tests for both infectious and non-infectious causes of acute illness. In the real world, only 30 to 40% of empiric broad-spectrum antibiotic administrations are appropriate, contributing to the emergence of antimicrobial resistant bacteria, toxicity related to antibiotic administration, and costs. The aim of this review article is to show that the use of biomarkers, such as the Pancreatic Stone Protein (PSP) as an example, helps in guiding the clinician to diagnose and manage sepsis. Over 600 peer-reviewed publications have studied the physiology of PSP and more than 50 evaluated its usefulness to screen for the development of nosocomial sepsis and diagnose sepsis.

show abstract

“…The detection principle of this method is based on the interactions between biomolecules, utilizing fluorescence resonance energy transfer luminescence and silica gel microspheres as the carrier, which has the characteristics of high sensitivity and specificity, low background noise, minimal sample requirements, low consumption, simple analytical operation, and a wide range of detectable targets [ 25 ]. AlphaLISA uses the specific binding reaction between antigen and antibody to reduce the distance between photoreceptor microspheres and luminescent microspheres to less than 200 nm, resulting in fluorescence emission through chemical reaction [ 26 , 27 ]. AlphaLISA employs a higher wavelength excitation light and chemical energy from the reaction to emit shorter wavelength light, resulting in significantly reduced background fluorescence and enhanced interference resistance.…”

Section: Introductionmentioning

confidence: 99%

“…Compared with ELISA and chemiluminescent immunoassays, AlphaLISA avoids the necessity to clarify fractions not reacting specifically, eliminates the washing step, and reduces the assay time [ 28 ]. This versatile technology has been successfully applied for the detection of everything from proteins to peptides and a variety of small molecule compounds, with applications ranging from medicine to agriculture and food [ 26 , 27 , 29 , 30 ]. This study aims to establish a novel rapid and accurate AlphaLISA assay for OA, which is expected to significantly contribute to the field of marine toxin detection.…”

Section: Introductionmentioning

confidence: 99%

Okadaic Acid Detection through a Rapid and Sensitive Amplified Luminescent Proximity Homogeneous Assay

Qin

Kuang

et al. 2023

Toxins

Self Cite

View full text Add to dashboard Cite

Okadaic acid (OA), a marine biotoxin produced by microalgae, poses a significant threat to mariculture, seafood safety, and human health. The establishment of a novel, highly sensitive detection method for OA would have significant practical and scientific implications. Therefore, the purpose of this study was to develop an innovative approach for OA detection. A competitive amplified luminescent proximity homogeneous assay (AlphaLISA) was developed using the principle of specific antigen–antibody binding based on the energy transfer between chemiluminescent microspheres. The method was non-washable, sensitive, and rapid, which could detect 2 × 10−2–200 ng/mL of OA within 15 min, and the detection limit was 4.55 × 10−3 ng/mL. The average intra- and inter-assay coefficients of variation were 2.54% and 6.26%, respectively. Detection of the actual sample results exhibited a good correlation with high-performance liquid chromatography. In conclusion, a simple, rapid, sensitive, and accurate AlphaLISA method was established for detecting OA and is expected to significantly contribute to marine biotoxin research.

show abstract

Development and application of a novel aldehyde nanoparticle-based amplified luminescent proximity homogeneous assay for rapid quantitation of pancreatic stone protein

Cited by 9 publications

References 37 publications

Development and application of an amplified luminescent proximity homogeneous assay-linked immunosorbent assay for the accurate quantification of kidney injury molecule-1

Development and application of an amplified luminescent proximity homogeneous assay-linked immunosorbent assay for the accurate quantification of kidney injury molecule-1

Usefulness of pancreatic stone protein measurement to screen and diagnose sepsis in the context of the Surviving Sepsis Campaign recommendations.

Okadaic Acid Detection through a Rapid and Sensitive Amplified Luminescent Proximity Homogeneous Assay

Contact Info

Product

Resources

About